Sign in
CompletedNo phase

Letrozole High Dose (10 mg) Compared to Letrozole Low Dose( 5 mg) for Ovarian Stimulation in Infertile Women With Polycystic Ovary Syndrome

Key facts

Who runs it
Mst.Sumyara Khatun
Where
Bangladesh1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
86 people enrolled
Started
1 Feb 2025
Ended
1 Feb 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tab.Letrozole 10 mg for 5 days
  • Tab.Letrozole 5mg for 5 days
Record updated
12 August 2026

Who can take part

Age
18 years to 35 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Age: 18-35 years old
  • BMI : 18-30 kg/m2
  • Diagnosed cases of PCOS patients according to Rotterdam criteria
  • Corrected hypothyroidism and hyperprolactinemia

Who cannot take part

  • History of hypersensitivity to letrozole; -; -
  • Women with other infertility factors (endometriosis, tubal and uterine causes of infertility)
  • Male factor infertility
  • Impaired hepatic or renal function

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if drug letrozole 10mg for 5 days works better than letrozole 5mg for 5 days for ovarian stimulation in infertile women with PCOS. It will also learn about the safety of drug letrozole . The main questions it aims to answer are:

Read full original descriptionShow less

What medical problems do participants have when taking drug letrozole? Researchers will compare drug letrozole 10mg for 5 days works better than letrozole 5 mg for 5 days for ovarian stimulation in infertile women with PCOS

Participants will:

The experimental arm (p1) will be treated with letrozole 10 mg for 5 days. The comparator arm (p2) will receive letrozole 5 mg for 5 days for ovulation induction for consecutive 3 months Treatment will start from the 2nd day of menstruation cycle or withdrawal bleeding after the baseline visit and investigations.

Ovarian response will be assessed by trans-vaginal monitoring of follicle growth around day 10 of menstrual cycle

The 2 groups in the trial

  • Tab.Letrozole 10 mg for 5 daysTreatment being tested

    Tab letrozole 10 mg for 5 days from day 2-3 of menstruation/withdrawal bleeding (5mg at morning and 5mg bed time for 5 days) for 3 cycle

  • Tab.Letrozole 5 mg for 5 daysExisting treatment, for comparison

    Tab letrozole 5mg for 5 days from day 2-3 of enstruation/withdrawal bleeding ( 5mg at bed time for 5 days) for three cycle

    Treatment: Tab.Letrozole 5mg for 5 days

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
12 August 2026